Gilead Sciences Q2 2024 Adj. EPS $2.01 Beats $1.60 Estimate, Sales $6.954B Beat $6.719B Estimate
Portfolio Pulse from Benzinga Newsdesk
Gilead Sciences (NASDAQ:GILD) reported strong Q2 2024 earnings, with an adjusted EPS of $2.01 beating the $1.60 estimate and sales of $6.954 billion surpassing the $6.719 billion estimate. This represents a significant year-over-year increase in both earnings and sales.
August 08, 2024 | 8:03 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Gilead Sciences reported Q2 2024 earnings of $2.01 per share, beating the $1.60 estimate by 25.62%. Sales of $6.954 billion also surpassed the $6.719 billion estimate. This strong performance indicates robust growth and could positively impact the stock price in the short term.
The significant beat on both EPS and sales estimates, along with strong year-over-year growth, suggests positive investor sentiment and potential upward movement in GILD's stock price.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100